Results 61 to 70 of about 41,221 (142)

A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan. [PDF]

Front Med (Lausanne), 2023
Ito T, Kaku-Ito Y, Ohno F, Nakahara T.
europepmc   +1 more source

Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study. [PDF]

ESMO Open, 2023
Colard-Thomas J, Manceron C, Duflos C, Herman F, Simon M, Maria ATJ, Faillie JL, Viala M, Palassin P.   +8 more
europepmc   +1 more source

Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen

Frontiers in Pediatrics
BackgroundRecombinant factor IX–albumin fusion protein (rIX-FP) enables extended-interval prophylaxis for hemophilia B. While higher trough levels with reduced dosing frequency have been shown vs.
Naoki Terasaka, William Mckeand
doaj   +1 more source

Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic. [PDF]

Respir Med Res, 2023
Veron M, Pierret T, Pérol M, Bettega F, Benet J, Denis N, Moro-Sibilot D, Swalduz A, Toffart AC.   +8 more
europepmc   +1 more source

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations

Clinical Interventions in Aging, 2008
John SunyeczMenopauseRx, Inc., Hopwood, PA, USAAbstract: Postmenopausal osteoporosis is common and underrecognized among elderly women. Osteoporotic fractures cause disability and disfigurement and threaten patients’ mobility, independence, and ...
John Sunyecz
doaj  

Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life

Drug Design, Development and Therapy, 2020
Suein Choi,1,2 Sangil Jeon,3 Dong-Seok Yim,1,2 Seunghoon Han1,2 1Pharmacometrics Institute for Practical Education and Training (PIPET), College of Medicine, The Catholic University of Korea, Seoul, Korea; 2Department of Pharmacology, College of Medicine,
Choi S, Jeon S, Yim DS, Han S
doaj  

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2021
Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, Kleinschnitz C, Kleinschnitz K, Rogall R, Pape K, Bittner S, Zipp F, Warnke C, Goereci Y, Schroeter M, Ingwersen J, Aktas O, Klotz L, Ruck T, Wiendl H, Meuth SG.   +20 more
europepmc   +1 more source

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes". [PDF]

Mult Scler, 2022
Rolfes L, Meuth SG.
europepmc   +1 more source

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience. [PDF]

J Cent Nerv Syst Dis, 2022
Perncezky J, Sellner J.
europepmc   +1 more source

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic. [PDF]

Neurotherapeutics, 2022
Zanghì A, Avolio C, Signoriello E, Abbadessa G, Cellerino M, Ferraro D, Messina C, Barone S, Callari G, Tsantes E, Sola P, Valentino P, Granella F, Patti F, Lus G, Bonavita S, Inglese M, D'Amico E.   +17 more
europepmc   +1 more source